The Centers for Disease Control and Prevention (CDC) is inviting research proposals through a cooperative agreement to identify and evaluate potential risk factors for Amyotrophic Lateral Sclerosis (ALS). The opportunity encourages studies focusing on various aspects such as military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents, with four distinct funding options available to support both established and exploratory research. This initiative aims to enhance understanding of ALS risk factors, particularly in affected populations, and to analyze biological samples related to the Guamanian ALS cluster. Interested applicants can reach out to Dr. Candis Hunter at ncipc_erpo@cdc.gov or by phone at 770-488-1347. The total estimated funding for this program is $7.5 million, with individual awards ranging from $0 to $500,000, and proposals are due by December 1, 2025, with awards expected to be announced by August 28, 2026.

CDC/ATSDR is inviting research proposals to study risk factors for Amyotrophic Lateral Sclerosis (ALS). Studies on military service, contact sports, traumatic brain injury, neuroinflammation, and infections agents and exposures are encourages. Funding will be for four funding options: Option A - Support research with strong existing evidence such as studies on known environmental or genetic risk factors, research that improves past studies with better data, or investigations linking risk factors to ALS diagnosis and treatment; Option B - Support new and exploratory research on ALS risk factors such as studies on risk factors with little existing evidence or research using innovative methods; Option C - Understand ALS risk in affected populations, such as studies involving military veterans or investigations of ALS risk factors impacting this population; Option D - Analyze biological samples from the Guamanian ALS cluster such as investigation of disease mechanisms and environmental factors, exposure routes, genetic studies and biomarkers and how this could lead to mitigation therapeutics, diagnostics or prevention. 

Buyer

Award Range

Eligible Applicants

Funding Category

Funding Instrument

Opportunity Category

Cost Sharing or Matching Requirement

Original Source